| Primary |
| Benign Prostatic Hyperplasia |
34.2% |
| Product Used For Unknown Indication |
15.4% |
| Hypertension |
8.7% |
| Lower Urinary Tract Symptoms |
4.7% |
| Prostatomegaly |
4.7% |
| Depression |
3.4% |
| Dysuria |
3.4% |
| Atrial Fibrillation |
2.7% |
| Pollakiuria |
2.7% |
| Analgesic Therapy |
2.0% |
| Asthma |
2.0% |
| Cardiomyopathy |
2.0% |
| Hypothyroidism |
2.0% |
| Micturition Disorder |
2.0% |
| Pneumonia |
2.0% |
| Urinary Retention |
2.0% |
| Urinary Tract Disorder |
2.0% |
| Bladder Disorder |
1.3% |
| Cerebrovascular Accident |
1.3% |
| Diabetes Mellitus |
1.3% |
|
| Gynaecomastia |
19.6% |
| Urinary Retention |
12.5% |
| Hallucination |
5.4% |
| Oedema Peripheral |
5.4% |
| Off Label Use |
5.4% |
| Orthostatic Hypotension |
5.4% |
| Vision Blurred |
5.4% |
| Hypersensitivity |
3.6% |
| Hypotension |
3.6% |
| Jaundice |
3.6% |
| Malaise |
3.6% |
| Musculoskeletal Stiffness |
3.6% |
| Overdose |
3.6% |
| Platelet Count Decreased |
3.6% |
| Pruritus |
3.6% |
| Rhinitis |
3.6% |
| Surgery |
3.6% |
| Abasia |
1.8% |
| Adverse Event |
1.8% |
| Ageusia |
1.8% |
|
| Secondary |
| Benign Prostatic Hyperplasia |
26.2% |
| Lower Urinary Tract Symptoms |
12.3% |
| Analgesic Therapy |
9.2% |
| Cerebrovascular Accident |
6.2% |
| Blood Cholesterol Abnormal |
3.1% |
| Depression |
3.1% |
| Diabetes Mellitus |
3.1% |
| Dyspepsia |
3.1% |
| Dysuria |
3.1% |
| Erectile Dysfunction |
3.1% |
| Gastric Ph Decreased |
3.1% |
| Gout |
3.1% |
| Hypertension |
3.1% |
| Muscle Spasms |
3.1% |
| Nocturia |
3.1% |
| Osteoporosis |
3.1% |
| Prostatic Disorder |
3.1% |
| Urinary Hesitation |
3.1% |
| Bladder Dysfunction |
1.5% |
| Hydronephrosis |
1.5% |
|
| Orthostatic Hypotension |
15.0% |
| Malaise |
10.0% |
| Surgery |
10.0% |
| Urinary Retention |
10.0% |
| Haemorrhage |
5.0% |
| Hypertension |
5.0% |
| Hypotension |
5.0% |
| Incorrect Route Of Drug Administration |
5.0% |
| Nocturia |
5.0% |
| Off Label Use |
5.0% |
| Overdose |
5.0% |
| Pulmonary Oedema |
5.0% |
| Sexual Dysfunction |
5.0% |
| Urinary Incontinence |
5.0% |
| Vitreous Disorder |
5.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
46.4% |
| Hepatitis C |
10.7% |
| Adverse Event |
7.1% |
| Plasma Cell Myeloma |
7.1% |
| Prophylaxis |
7.1% |
| Acute Myeloid Leukaemia |
3.6% |
| Benign Prostatic Hyperplasia |
3.6% |
| Dementia Alzheimer's Type |
3.6% |
| Hyperlipidaemia |
3.6% |
| Hypertension |
3.6% |
| Type 2 Diabetes Mellitus |
3.6% |
|
| Alanine Aminotransferase Increased |
12.5% |
| Hyponatraemia |
12.5% |
| Monarthritis |
12.5% |
| Oedematous Pancreatitis |
12.5% |
| Plasma Cell Myeloma |
12.5% |
| Pneumonia |
12.5% |
| Psychomotor Hyperactivity |
12.5% |
| Upper Gastrointestinal Haemorrhage |
12.5% |
|
